MX352274B - Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal. - Google Patents

Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.

Info

Publication number
MX352274B
MX352274B MX2014004712A MX2014004712A MX352274B MX 352274 B MX352274 B MX 352274B MX 2014004712 A MX2014004712 A MX 2014004712A MX 2014004712 A MX2014004712 A MX 2014004712A MX 352274 B MX352274 B MX 352274B
Authority
MX
Mexico
Prior art keywords
methods
inflammatory bowel
bowel disease
ibd
disease diagnosis
Prior art date
Application number
MX2014004712A
Other languages
English (en)
Spanish (es)
Other versions
MX2014004712A (es
Inventor
Singh Sharat
Princen Fred
Lockton Steven
J Croner Lisa
A Fletcher Frederick
Stockfisch Thomas
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2014004712A publication Critical patent/MX2014004712A/es
Publication of MX352274B publication Critical patent/MX352274B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70542—CD106
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Primary Health Care (AREA)
  • Physiology (AREA)
MX2014004712A 2011-10-21 2012-10-19 Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal. MX352274B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161550293P 2011-10-21 2011-10-21
US201161553853P 2011-10-31 2011-10-31
US201161567096P 2011-12-05 2011-12-05
US201161570271P 2011-12-13 2011-12-13
PCT/US2012/061202 WO2013059732A1 (en) 2011-10-21 2012-10-19 Methods for improving inflammatory bowel disease diagnosis

Publications (2)

Publication Number Publication Date
MX2014004712A MX2014004712A (es) 2014-11-14
MX352274B true MX352274B (es) 2017-11-16

Family

ID=48141435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004712A MX352274B (es) 2011-10-21 2012-10-19 Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.

Country Status (9)

Country Link
US (2) US8715943B2 (enExample)
EP (1) EP2769321B1 (enExample)
JP (1) JP2015502740A (enExample)
AU (1) AU2012325798B2 (enExample)
CA (1) CA2852954A1 (enExample)
IL (1) IL232167A0 (enExample)
MX (1) MX352274B (enExample)
SG (1) SG11201401536QA (enExample)
WO (1) WO2013059732A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
NZ619527A (en) 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2014182689A1 (en) * 2013-05-06 2014-11-13 Yacyshyn Bruce R Method of using biomarkers in predicting inflammatory bowel disease
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
CA2913108A1 (en) * 2013-05-24 2014-11-27 Nestec S.A. Pathway specific assays for predicting irritable bowel syndrome diagnosis
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US11568982B1 (en) 2014-02-17 2023-01-31 Health at Scale Corporation System to improve the logistics of clinical care by selectively matching patients to providers
US11227667B2 (en) * 2014-07-11 2022-01-18 Matatu, Inc. Use of a gut microbiome as a predictor of animal growth or health
CN104131102B (zh) * 2014-08-07 2016-06-15 马飞 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒
US11809501B2 (en) 2014-08-28 2023-11-07 Ebay Inc. Systems, apparatuses, and methods for providing a ranking based recommendation
JP2018504584A (ja) * 2014-12-02 2018-02-15 ネステク ソシエテ アノニム 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
KR102116485B1 (ko) 2015-01-20 2020-05-28 난토믹스, 엘엘씨 고분화 방광암의 화학요법에 대한 반응 예측을 위한 시스템들 및 방법들
CN107980162A (zh) * 2015-03-03 2018-05-01 南托米克斯有限责任公司 基于组合的研究建议系统和方法
US11037070B2 (en) * 2015-04-29 2021-06-15 Siemens Healthcare Gmbh Diagnostic test planning using machine learning techniques
WO2017136511A1 (en) * 2016-02-02 2017-08-10 Maximus Diagnostic Technologies Llc Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
JP7111322B2 (ja) * 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
US10409734B1 (en) * 2017-03-27 2019-09-10 Symantec Corporation Systems and methods for controlling auxiliary device access to computing devices based on device functionality descriptors
CN108784666B (zh) * 2017-05-04 2023-01-13 深圳市生码医疗科技有限公司 连续监测心血管的精准医疗系统及数据处理方法
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
US11972841B2 (en) * 2017-12-18 2024-04-30 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
WO2019195146A1 (en) 2018-04-03 2019-10-10 Boston Scientific Scimed, Inc. Systems and methods for diagnosing and/or monitoring disease
WO2020009949A1 (en) * 2018-07-05 2020-01-09 Boston Scientific Scimed, Inc. Devices, systems, and methods for determining inflammation and/or fibrosis
CA3108719A1 (en) * 2018-08-21 2020-02-27 Bruce R. Yacyshyn Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
CA3121167A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020117795A1 (en) * 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
WO2020219549A1 (en) * 2019-04-23 2020-10-29 Cedars-Sinai Medical Center Methods and systems for assessing inflammatory disease with deep learning
JP2022532381A (ja) * 2019-05-16 2022-07-14 プロサイセデクス インコーポレイティド Ｖｃａｍ－１及びカルプロテクチンのための分析検出方法
CN110373457B (zh) * 2019-06-20 2023-03-14 镇江市第一人民医院 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用
CN111417124A (zh) * 2019-06-28 2020-07-14 西南交通大学 在认知无线网络环境下频谱感知的方法
CN115605615A (zh) * 2020-03-06 2023-01-13 美国控股实验室公司（Us） 用于血红蛋白a(hba)检测和基因分型的测定
US11610679B1 (en) * 2020-04-20 2023-03-21 Health at Scale Corporation Prediction and prevention of medical events using machine-learning algorithms
EP4162076A4 (en) * 2020-06-03 2024-10-02 Cedars-Sinai Medical Center TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
US12094582B1 (en) 2020-08-11 2024-09-17 Health at Scale Corporation Intelligent healthcare data fabric system
US12080428B1 (en) 2020-09-10 2024-09-03 Health at Scale Corporation Machine intelligence-based prioritization of non-emergent procedures and visits
WO2022061346A1 (en) * 2020-09-16 2022-03-24 Northwestern University Classification of functional lumen imaging probe data
CA3194324A1 (en) * 2020-10-05 2022-04-14 Dermot MCGOVERN Methods and systems for stratifying inflammatory bowel disease patients
KR20240043724A (ko) * 2020-12-04 2024-04-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 생물학적 장애의 동적 면역조직화학 프로파일링을 위한 시스템 및 방법
WO2022125867A1 (en) * 2020-12-11 2022-06-16 Icahn School Of Medicine At Mount Sinai Methods of monitoring inflammatory bowel diseases
JP7655720B2 (ja) * 2020-12-18 2025-04-02 花王株式会社 ストレスマーカー及びそれを用いた慢性ストレスレベルの検出方法
JP7655721B2 (ja) * 2020-12-18 2025-04-02 花王株式会社 疲労マーカー及びそれを用いた疲労の検出方法
PE20231680A1 (es) 2021-02-17 2023-10-19 Dr Falk Pharma Gmbh Anticuerpos anti-cd30l y usos de estos
US20240404053A1 (en) * 2021-09-22 2024-12-05 Janssen Research & Development, Llc Automatic Estimation of Ulcerative Colitis Severity from Endoscopy Videos USING ORDINAL MULTI-INSTANCE LEARNING
US20250149178A1 (en) * 2022-01-28 2025-05-08 University Of Southern California Identifying non-disease patients using a disease related assay and analysis in the liquid biopsy

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277250A (en) 1979-12-10 1981-07-07 Baylor College Of Medicine Methods for detecting and quantifying occult blood
JPH0684970B2 (ja) 1987-03-31 1994-10-26 株式会社京都医科学研究所 糞便中の潜血検出方法
US5081040A (en) 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
JPH0736013B2 (ja) 1991-04-27 1995-04-19 一男 田畑 潜血検出用試薬
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
EP0615129B1 (en) 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5932429A (en) 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5750479A (en) 1997-02-14 1998-05-12 Bandon Corp. Enclosed fluid system conditioner and process therefor
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
AU5161800A (en) 1999-05-24 2000-12-12 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
US6821739B2 (en) 2000-10-13 2004-11-23 The Regents Of The University Of California Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens
US20020150626A1 (en) 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for delivery of nucleic acids
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
CA2427471C (en) 2000-10-30 2010-12-21 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
DK1330525T3 (da) 2000-10-30 2013-03-04 Univ Michigan NOD2-nukleinsyrer og proteiner
US20050164929A1 (en) 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
ES2325059T3 (es) 2000-11-14 2009-08-25 Techlab, Inc. Metodo para diferenciar el sindrome del intestino irritable de la enfermedad inflamatoria intestinal (ibd) y para seguir personas con ibd usando la lactoferrina endogena total como marcador.
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20030204507A1 (en) 2002-04-25 2003-10-30 Li Jonathan Qiang Classification of rare events with high reliability
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
DE60321027D1 (de) 2002-10-25 2008-06-26 Techlab Inc Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon
US20070275424A1 (en) 2002-11-22 2007-11-29 Andrew Gewirtz Diagnostic Tests and Methods for Diagnosing Inflammatory Bowel Disease
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
EP1617214A4 (en) 2003-04-23 2008-01-23 Eisai R&D Man Co Ltd METHOD FOR CREATING A DISEASE PROGNOSTIC MODEL, METHOD FOR PREDICTING DISEASE PROGNOSIS USING THE MODEL, DEVICE FOR PREDICTING PROGNOSIS OF DISEASE USING THE MODEL, PROGRAM THEREFOR, AND RECORDING MEDIUM
US20040242972A1 (en) 2003-05-28 2004-12-02 General Electric Company Method, system and computer product for prognosis of a medical disorder
US20050060295A1 (en) 2003-09-12 2005-03-17 Sensory Networks, Inc. Statistical classification of high-speed network data through content inspection
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
WO2005078452A1 (en) 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US7759079B2 (en) 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
CA3204588A1 (en) 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008141148A2 (en) 2007-05-10 2008-11-20 Cedars-Sinai Medical Center Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease
WO2008109782A2 (en) 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CA2719384A1 (en) 2008-03-27 2009-10-01 Jx Nippon Oil & Energy Corporation Fuel cell system and method for load following operation of the same
US20100129838A1 (en) * 2008-11-11 2010-05-27 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
ES2509616T3 (es) * 2009-06-25 2014-10-17 Nestec S.A. Procedimientos de diagnóstico del síndrome del intestino irritable
CA2781654A1 (en) * 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
EP2576838A4 (en) 2010-06-04 2019-05-15 Nestec S.A. METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE

Also Published As

Publication number Publication date
US8715943B2 (en) 2014-05-06
US20130225439A1 (en) 2013-08-29
IL232167A0 (en) 2014-06-30
AU2012325798B2 (en) 2015-11-26
EP2769321A1 (en) 2014-08-27
WO2013059732A1 (en) 2013-04-25
EP2769321B1 (en) 2016-06-01
JP2015502740A (ja) 2015-01-29
MX2014004712A (es) 2014-11-14
SG11201401536QA (en) 2014-05-29
US20150072879A1 (en) 2015-03-12
CA2852954A1 (en) 2013-04-25
HK1200933A1 (zh) 2015-08-14
AU2012325798A1 (en) 2013-05-16
EP2769321A4 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
MX2012014096A (es) Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX2014007040A (es) Diagnostico de falla de un sistema elevador y los componentes del mismo por medio de un sensor.
WO2013084002A3 (en) Method for detecting nucleosome adducts
FR2984522B1 (fr) Dispositif de detection de la proximite d'un objet, comprenant des photodiodes spad
NZ705411A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340725B (es) Indicador vaginal para detectar biomarcadores de buena salud.
EA202191354A1 (ru) Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
FR2976521B1 (fr) Procede de detection univoque du seuil d'usure d'un pneumatique
EP2757160A3 (en) Gene expression markers for Crohn's disease
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MY185376A (en) Subsea leak-detection system
WO2016034945A3 (en) Stuck pipe prediction
MX2014010100A (es) Sistema y metodo para determinar una propiedad de un objeto, y una valvula.
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
MX352502B (es) Detector de fugas de fluido.
Mertens et al. Evaluation of phenotypic markers in full genome sequences of avian influenza isolates from California
WO2011085057A3 (en) Methods for detecting insulin autoantibody
CO7061090A2 (es) Resistencia mejorada a la corrosión cuando se utilizan agentes de quelación en equipo que contiene acero carbono
EP2686437A4 (en) MUCIN 5B AS A BIOMARKER FOR PANCREAS CYSTIC FLUID FOR THE ACCURATE DIAGNOSIS OF MUZINOUS CYCLES AND OTHER MARKERS FOR THE DETECTION OF PANCREAS MALIGNITIES
GB201018767D0 (en) Touch detection
NZ612673A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
UA103283C2 (ru) Способ выявления компонентов клеточной стенки дрожжей
TR201909377T4 (tr) Bir eriyik banyosunda bir işletim koşulunun belirlenmesine yönelik bir algılama cihazına sahip üstten üflemeli, üfleme borusu kullanımlı enjektör reaktör sistemi.

Legal Events

Date Code Title Description
FG Grant or registration